畢馬威料香港IPO市場短期仍有挑戰 今年底有望重返全球IPO五甲
畢馬威最新發表的《中國內地及香港IPO市場2023年第三季度回顧》報告指,在目前約110宗上市申請的支持下,香港有望在2023年年底重返全球IPO五甲。不過。由於利率持續高企和經濟增長放緩,預計香港IPO市場表現在短期內仍面臨挑戰。
報告提到,A股IPO市場繼續領先全球,2023年至今累積貢獻全球募資總額約一半,交易宗數則佔全球約五分之一。納斯達克證券交易所今年憑藉一宗超大規模的半導體與軟件設計公司上市項目,募資總額增至109億美元,全球排名躍升至第三。與此同時,紐約證券交易所穩居全球第四位;兩間交易所去年均五甲不入,今年的表現有顯著進步。
今年首三季,上海證券交易所和深圳證券交易所分別募資287億美元和198億美元,較去年同期分別減少42%和23%。儘管募資總額有所下降,A股IPO申請宗數仍然相對穩定,目前約有820家企業申請上市,由此可見市場對A股IPO需求殷切。從A股IPO市場的募資額來看,排名前三的企業均與半導體生產相關,反映中國內地重視半導體行業發展。訊息技術、媒體及電訊和工業製造業佔目前IPO申請人近七成,預計將成為A股市場長期增長的主要推動力。
畢馬威資本市場合夥人劉大昌表示,中國證監會為振興A股資本市場而推行的措施有望在短期內平衡IPO步伐,並促進資本市場更健康和可持續的長遠發展。隨著金融監管措施不斷完善,加上上市申請數目保持穩定,A股證券交易所在未來幾年將繼續高踞全球IPO排行前列。
香港IPO市場今年首三季度僅錄得44宗IPO上市,募資總額為246億港元,分別較去年同期減少65%和15%,拖累香港下跌至全球IPO排名第八位。雖然新股市況仍然低迷,但上市申請宗數繼續穩步積累,截至2023年9月30日達到約110間。有別於香港整體IPO市場,未盈利生物科技公司率先顯露增長勢頭,迄今有六間公司成功上市,超越去年同期的四間,再次彰顯香港作為生物科技公司集資樞紐的韌性。截至9月30日,共有29間訊息技術、媒體及電訊公司以及20間醫療保健及生物科技公司申請在香港上市,其中包括9間未盈利生物科技公司。這兩個行業合計佔香港新股申請宗數近一半,有望幫助香港在年底重返全球IPO排名前五位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.